Ishwaria Subbiah appointed SCRI’s executive director for Cancer Care Equity & Professional Wellness

Move of the month

Ishwaria Subbiah appointed as SCRI’s executive director for Cancer Care Equity and Professional Wellness

Oncology research organisation, Sarah Cannon Research Institute (SCRI) has announced that Ishwaria Subbiah MD MS, has been appointed to the role of executive director of Cancer Care Equity and Professional Wellness.

In her new role, Subbiah will focus on the reduction of cancer outcomes disparities and the diversification of clinical trial participation within SCRI’s combined research network, which comprises over 1,300 physicians in more than 250 locations across the US.

Howard A Burris III MD, president of SCRI, commented: “Participating in a clinical trial is the first step in fighting cancer, and we must ensure that more patients – especially underserved populations – can access these treatment options. With Ishwaria’s leadership, we can implement strategies to reduce barriers while accelerating drug development and improving patient outcomes.”

Commenting on her new role, Dr Subbiah said: “Broadening access to high-quality cancer care and cutting-edge cancer therapies on clinical trials is possible by bringing all stakeholders to the same table and enacting changes together. With SCRI’s national reach, we have the ability to develop transformational approaches to diversify clinical trial recruitment and reduce care disparities at an unprecedented scale. At the same time, we have an opportunity to also focus on workplace experiences for thousands of clinicians engaged in research across SCRI’s network. By strengthening our workforce, we can strengthen the fight against cancer for every individual we treat.”

LEON appoints Dr Setu Kasera as CSO

LEON has announced the appointment of Dr Setu Kasera as its new chief scientific officer (CSO) effective 15 June 2023.

Patrick Johnson appointed to Aviceda Therapeutics’ board of directors

Private clinical-stage biotech, Aviceda Therapeutics has announced that it has appointed Patrick Johnson to its board of directors.

Alex C Sapir appointed as Fulcrum Therapeutics’ CEO

Clinical stage biopharmaceutical company, Fulcrum Therapeutics, has announced the appointment of Alex C Sapir as CEO and president effective 1 July 2023.

Optibrium appoints Dr Hamed Tabatabaei Ghomi as head of research

Optibrium has announced the appointment of Dr Hamed Tabatabaei Ghomi as head of research, this is the latest appointment in a series of senior level hires. Ghomi brings with him experience of strategic and industrial research in the bioinformatics space, as well as a positive academic record.

Roz Bekker appointed managing director of Janssen UK and Ireland

The Janssen pharmaceutical companies, part of Johnson & Johnson (J&J), has announced the appointment of Roz Bekker as the new managing director of Janssen UK and Ireland.

LEON appoints Dr Setu Kasera as CSO

Patrick Johnson appointed to Aviceda Therapeutics’ board of directors

Alex C Sapir appointed as Fulcrum Therapeutics’ CEO

Optibrium appoints Dr Hamed Tabatabaei Ghomi as head of research

Roz Bekker appointed managing director of Janssen UK and Ireland

Pharmafocus

Categories

Social Footprints